Arbutus Biopharma Corp ABUS

Healthcare Biotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

NDAQ:ABUS - Post by User

Arbutus Biopharma Corp

Bullboard Posts

Comment by sometoaston Oct 17, 2007 11:47am

296 Views

Post# 13587657

RE: Wonder if TKM knew about Merck/Protiva

The problem I have with the Protiva news release is that for Merck to pay Protiva (unless it was a very trivial amount), they probably did some due diligence of their own and concluded that Protiva had a reasonable claim to the technology. This likely goes against the due diligence that Alnylam and others must have done when they signed up with Tekmira/Inex. The Merck deal does muddy the waters in my mind (up till now I really thought that Protiva did not have much of a case....). Am I missing something?

Bullboard Posts

The Market Online’s Weekly Cannabis Report – Nov. 15, 2024